Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study

This study has been terminated.
(See termination reason in detailed description.)
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01089725
First received: March 11, 2010
Last updated: June 27, 2013
Last verified: June 2013

March 11, 2010
June 27, 2013
March 2010
November 2010   (final data collection date for primary outcome measure)
  • Change from Baseline to Week 16 in the Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain subscale [ Time Frame: Baseline to 16 weeks ] [ Designated as safety issue: No ]
  • Change from Baseline to Week 16 in the WOMAC Physical Function subscale [ Time Frame: Baseline to 16 weeks ] [ Designated as safety issue: No ]
  • Change from Baseline to Week 16 in the Patient Global Assessment of Osteoarthritis [ Time Frame: Baseline to 16 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01089725 on ClinicalTrials.gov Archive Site
  • WOMAC Pain subscale change from Baseline to Weeks 1, 2, 4, 8, and 12 [ Time Frame: Baseline to Weeks 1, 2, 4, 8, and 12 ] [ Designated as safety issue: No ]
  • WOMAC Physical Function subscale change from Baseline to Weeks 1, 2, 4, 8, and 12 [ Time Frame: Baseline to Weeks 1, 2, 4, 8, and 12 ] [ Designated as safety issue: No ]
  • Patient Global Assessment of Osteoarthritis (5-point Likert scale) change from Baseline to Weeks 1, 2, 4, 8, and 12 [ Time Frame: Baseline to Weeks 1, 2, 4, 8, and 12 ] [ Designated as safety issue: No ]
  • Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) and OsteoArthritis Research Society International (OARSI) responder index at Weeks 1, 2, 4, 8, 12, and 16 [ Time Frame: Weeks 1, 2, 4, 8, 12, and 16 ] [ Designated as safety issue: No ]
  • Treatment Response: Reduction in the WOMAC Pain subscale of greater than or equal to: 30%, 50%, 70%, and 90% at Weeks 1, 2, 4, 8, 12, and 16 [ Time Frame: Weeks 1, 2, 4, 8, 12, and 16 ] [ Designated as safety issue: No ]
  • Cumulative distribution of percent change from Baseline in the WOMAC Pain subscale score to Weeks 1, 2, 4, 8, 12 and 16 (endpoint for summary only) [ Time Frame: Weeks 1, 2, 4, 8, 12 and 16 ] [ Designated as safety issue: No ]
  • Treatment Response: Improvement of greater than or equal to 2 points in Patient Global Assessment of Osteoarthritis at Weeks 1, 2, 4, 8, 12, and 16 • [ Time Frame: Weeks 1, 2, 4, 8, 12, and 16 ] [ Designated as safety issue: No ]
  • Average pain score in the index knee change from Baseline to Weeks 1, 2, 4, 8, 12, and 16 [ Time Frame: Baseline to Weeks 1, 2, 4, 8, 12, and 16 ] [ Designated as safety issue: No ]
  • WOMAC Stiffness subscale change from Baseline to Weeks 1, 2, 4, 8, 12, and 16 [ Time Frame: Baseline to Weeks 1, 2, 4, 8, 12, and 16 ] [ Designated as safety issue: No ]
  • WOMAC Average change from Baseline to Weeks 1, 2, 4, 8, 12 and 16 [ Time Frame: Baseline to Weeks 1, 2, 4, 8, 12 and 16 ] [ Designated as safety issue: No ]
  • WOMAC Pain Subscale Item: Pain When Walking on a Flat Surface, change from Baseline to Weeks 1, 2, 4, 8, 12 and 16 [ Time Frame: Baseline to Weeks 1, 2, 4, 8, 12 and 16 ] [ Designated as safety issue: No ]
  • WOMAC Pain Subscale Item: Pain When Going Up or Down Stairs, change from Baseline to Weeks 1, 2, 4, 8, 12 and 16 [ Time Frame: Baseline to Weeks 1, 2, 4, 8, 12 and 16 ] [ Designated as safety issue: No ]
  • SF-36v2TM Health Survey change from Baseline to Week 16 (8 domains plus Physical Component Summary and Mental Component Summary) [ Time Frame: Baseline to Week 16 ] [ Designated as safety issue: No ]
  • Time to discontinuation due to Lack of Efficacy [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
  • Incidence of patients who use rescue medication during Weeks 1, 2, 4, 8, 12, and 16 [ Time Frame: Weeks 1, 2, 4, 8, 12, and 16 ] [ Designated as safety issue: No ]
  • Number of days of rescue medication use during Weeks 1, 2, 4, 8, 12, and 16 [ Time Frame: Weeks 1, 2, 4, 8, 12, and 16 ] [ Designated as safety issue: No ]
  • Amount (mg) of rescue medication taken during Weeks 1, 2, 4, 8, 12, and 16 [ Time Frame: Weeks 1, 2, 4, 8, 12, and 16 ] [ Designated as safety issue: No ]
  • Adverse Events [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
  • Clinical laboratory testing (chemistry, hematology, urinalysis) [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
  • Electrocardiogram (ECG) [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
  • Neurologic exam (Neuropathy Impairment Score [NIS]) [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
  • Anti Drug Antibody (ADA) assessments predose at Baseline, Week 8 and 16, and at Week 24, or Early Termination [ Time Frame: Baseline, Week 8 and 16, and at Week 24, or Early Termination ] [ Designated as safety issue: Yes ]
  • Physical examinations [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
  • Vital signs [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
  • Injection/infusion site reactions [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
  • Measurement of plasma tanezumab concentrations at Baseline (predose), Week 1, Week 2, Week 4, Week 8 (predose), Week 12, Week 16, and Week 24 or early termination [ Time Frame: Baseline, Week 1, Week 2, Week 4, Week 8 (predose), Week 12, Week 16, and Week 24 ] [ Designated as safety issue: No ]
  • Measurement of serum total and/or bound and/or free NGF concentrations at Baseline (predose), Week 1, Week 2, Week 4, Week 8 (predose), Week 12, Week 16 and Week 24 or early termination [ Time Frame: Baseline , Week 1, Week 2, Week 4, Week 8 (predose), Week 12, Week 16 and Week 24 ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study
Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of Subcutaneous Administration Of Tanezumab In Patients With Osteoarthritis Of The Knee

This is an efficacy and safety study of 3 doses (2.5 mg, 5 mg and 10mg) of tanezumab administered subcutaneously versus placebo. This study will also compare a subcutaneous (SC) administration of 10 mg of tanezumab) with an intravenous (IV) administration of 10 mg of tanezumab. Each person will receive an IV infusion and a SC infusion. The study will last 16 weeks for those who wish to enter a 64-week extension study or 24 weeks for those who do not.

This study was terminated on 08 Nov 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
  • Osteoarthritis
  • Arthritis
  • Pain
  • Biological: Placebo IV
    1 ml of placebo administered SC and IV once every 8 weeks.
  • Biological: Placebo SC
    1 ml of placebo administered SC and IV once every 8 weeks.
  • Biological: Tanezumab SC
    1 ml tanezumab injection SC administered every 8 weeks
  • Biological: Placebo IV
    1 ml placebo administered IV every 8 weeks
  • Biological: Placebo IV
    1ml placebo administered IV every 8 weeks
  • Biological: Tanezumab IV
    1 ml tanezumab injection IV administered every 8 weeks
  • Biological: Placebo SC
    1ml placebo administered SC every 8 weeks
  • Placebo Comparator: Placebo
    Interventions:
    • Biological: Placebo IV
    • Biological: Placebo SC
  • Experimental: 2.5 mg tanezumab SC and placebo IV
    Interventions:
    • Biological: Tanezumab SC
    • Biological: Placebo IV
  • Experimental: 5 mg tanezumab SC and placebo IV
    Interventions:
    • Biological: Tanezumab SC
    • Biological: Placebo IV
  • Experimental: 10 mg tanezumab SC and placebo IV
    Interventions:
    • Biological: Tanezumab SC
    • Biological: Placebo IV
  • Experimental: 10 mg tanezumab IV
    Interventions:
    • Biological: Tanezumab IV
    • Biological: Placebo SC
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
385
November 2010
November 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of osteoarthritis (OA) of the knee according to American College of Rheumatology (ACR) criteria with a Kellgren- Lawrence score of greater than or equal to 2
  • 18 years of age or greater
  • Two methods of birth control one of which must be barrier if of childbearing potential
  • Willing to discontinue pain medication except as permitted per protocol

Exclusion Criteria:

  • Pregnancy or wishing to be pregnant during the course of the study, lactating women
  • Body Mass Index (BMI) greater than 39
  • Clinically significant cardiac, neurological, psychiatric conditions and other conditions that are excluded by the protocol.
  • Previous exposure to a Nerve Growth Factor (NGF) antibody
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01089725
A4091027
Yes
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP